Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028 is registered in ClinicalTrials.gov with NovaDigm Therapeutics, Inc. as lead sponsor.

NCT NCT01926028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01926028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Lead sponsor
NovaDigm Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2013
Completion date
May 31, 2016
Enrollment
188 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

vulvovaginal candidiasis